5 Best Biotech Penny Stocks to Buy Now

3. Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Number of Hedge Fund Holders: 28

Mersana Therapeutics, Inc. (NASDAQ:MRSN) was losing value in late July after the company’s ovarian cancer treatment failed a pivotal trial.  Baird downgraded Mersana Therapeutics, Inc. (NASDAQ:MRSN) to Neutral from Overweight.

Insider Monkey’s database of 943 hedge funds shows that 28 funds reported having stakes in Mersana Therapeutics, Inc. (NASDAQ:MRSN). The most notable stakeholder of Mersana Therapeutics, Inc. (NASDAQ:MRSN) was Samuel Isaly’s OrbiMed Advisors with a $37 million stake in the company. The second biggest hedge fund stakeholder of Mersana Therapeutics, Inc. (NASDAQ:MRSN) during this period was Kurt Von Emster’s VenBio Select Advisor which had a $31 million stake.